Bridge Therapeutics Inc.

Buprenorphine May Be Safe, Effective for Acute Pain in Older Adults In a meta-analysis of 22 studies of 2,610 older adults (60 years+) buprenorphine was found as effective as conventional analgesia and, in some cases, reduced the need for breakthrough analgesia, reduce opioid consumption, and improve patient satisfaction. Studies were published between 1987 and 2023 across 10 countries and featured a variety of delivery mechanisms. For a more detailed summary see: https://lnkd.in/gzcwdCtB hashtag #painmedicine #opioids #acutepain #elderly

Bridge Therapeutics is developing novel therapeutics for treating pain and addiction. Learn more at Litestream family office forum. https://lnkd.in/eH2MgHHe

The FDA has approved Zurnai, the first nalmefene auto-injector for the emergency opioid overdose. Like naloxone (Narcan), nalmefene restores breathing to those suffering respiratory depression from opioids. It's key distinction is its longer duration of 1-4 hours versus 60-90 minutes for naloxone, reducing the monitoring frequency so that the effects of opioid toxicity do not return to wreak havoc. For more on the FDA's announcement see: https://lnkd.in/eMHuJ7N9 For a pharmacological comparison of nalmefene to naloxone see: https://lnkd.in/eBhx-FCy

Optimizing Palliative Care: Transitioning from Full Agonist Opioids to Low-Dose Buprenorphine A small study (n=19) showed that nearly 90% of patients rotated to tiny doses of buprenorphine had the same pain relief as usual (full agonist) opioids, though at 1/60th the opioid milligram equivalent (OME). For a full summary see: https://lnkd.in/giUeuMch #opioidaddiction #chronicpain

Study - Buprenorphine less available in Minority Communities. In recent years the Opioid Crisis has fallen disproportionately among Black and Native American or Alaska Native populations. Yet this study of 2018 data of prescribers and prescriptions in both urban and rural areas shows that treatment with buprenorphine is also less available. "[A]chieving more equitable buprenorphine access requires not only increasing the number of buprenorphine-prescribing clinicians serving diverse communities… it also requires efforts to promote greater buprenorphine prescribing among already prescribing clinicians." #opioidcrisis #opioidusedisorder #addiction https://lnkd.in/eZSxCjND

Big Improvement in Treating Addiction in Behind Bars "Just a few years ago, only a small percentage of jails were providing MOUD to the general population with OUD. Today, about 30% of jails provide buprenorphine and about 20% of jails provide methadone, two of the three FDA-approved MOUDs." See the full story at: https://lnkd.in/eQfw77Wt

Bridge Therapeutics at JP Morgan Week in San Fran (Jan 8-11) We are very excited to let you know that Bridge Therapeutics will be attending the J.P. Morgan Healthcare Conference in San Francisco, CA January 8-11, 2024. We anticipate hundreds of investors and key opinion leaders will attend this event. #jpmorgan #healthcare #conference #addictionmedicine #painmedicine https://lnkd.in/eZBPTdbM